Recent recommendations from the cIMPACT-NOW consortium suggest that EGFR amplification and combined chr7 gain and chr10 loss as well as TERT promoter mutation can be used to diagnose IDH wild type (WT) grade II/III gliomas that are likely to follow a more aggressive clinical disease course (Brat et al., 2018). The gene discussed is TERT; the disease is glioma.